M&A Deal Summary |
|
|---|---|
| Date | 2005-07-19 |
| Target | GlycArt Biotechnology AG |
| Sector | Life Science |
| Buyer(s) | Roche |
| Sellers(s) |
Gilde Healthcare
Capital A Investment Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 235M CHF |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1896 |
| Sector | Life Science |
| Employees | 100,920 |
| Revenue | 63.3B CHF (2022) |
Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 42 |
| Sector (Life Science) | 1 of 29 |
| Type (Add-on Acquisition) | 3 of 35 |
| Country (Switzerland) | 3 of 3 |
| Year (2005) | 1 of 1 |
| Size (of disclosed) | 19 of 29 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-02-10 |
Disetronic Holding AG
Burgdorf, Switzerland Disetronic, which is based in Burgdorf near Berne, Switzerland, has been a world leader in the research and development of insulin pumps and injection systems for the treatment of diabetes since 1984. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-03-29 |
454 Life Sciences
Branford, Connecticut, United States 454 Life Sciences develops and commercializes novel instrumentation for high-throughput DNA sequencing. Specific applications include whole-genome sequencing, RNA analysis and ultra-deep sequencing of target genes. The hallmarks of 454 Sequencing are its simple, unbiased sample preparation and massively parallel sequencing, which makes large-scale scientific projects feasible and more affordable. |
Buy | $140M |
| Category | Private Equity Firm |
|---|---|
| Founded | 1999 |
| PE ASSETS | 800M EUR |
| Size | Middle-Market |
| Type | Sector Focused |
Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest up to €30 million in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 30 |
| Sector (Life Science) | 1 of 16 |
| Type (Add-on Acquisition) | 1 of 15 |
| Country (Switzerland) | 1 of 1 |
| Year (2005) | 1 of 1 |
| Size (of disclosed) | 2 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-06-14 |
Chroma Therapeutics
Abingdon, United Kingdom Chroma Therapeutics is a new cancer drug discovery company with first-mover advantage in the field of chromatin biology. Chroma Therapeutics was founded in 2000 and is based in Abingdon, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-01-01 |
uniQure
Amsterdam, Netherlands uniQure is a gene therapy company that developed the first and only gene therapy product to receive regulatory approval in the European Union. Gene therapy is a technique for correcting defective or missing genes that cause diseases. uniQure is primarily focused on rare genetic diseases, and will also start developing gene therapies for chronic and degenerative diseases that affect larger populations. uniQure was founded in 1998 and is based in Amsterdam, the Netherlands. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1985 |
| Size | Middle-Market |
| Type | Sector Agnostic |
Capital A Investment Partners is a private equity firm specializing in management buyouts, management buy-ins, expansion/growth financing, shareholder replacement, and turnarounds. Capital A Investment Partners targets mid-sized Dutch companies invest in mature companies with positive and consistent cash generation that belong to the top of their sector. Capital A Investment Partners invest across all sectors. The Firm typically invests in a broad range of industry sectors with an investment of €5 - €50 million per transaction.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 34 |
| Sector (Life Science) | 1 of 1 |
| Type (Add-on Acquisition) | 2 of 16 |
| Country (Switzerland) | 1 of 1 |
| Year (2005) | 1 of 2 |
| Size (of disclosed) | 1 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-07-18 |
Xention
Cambridge, United Kingdom Xention is a biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation, an area in which it has developed considerable expertise. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-09-01 |
Loparex Group
Apeldoorn, Netherlands Loparex Group is a manufacturer of polycoated and silicone-coated papers and films, used in a wide variety of pressure sensitive adhesive applications. With in-depth technical expertise, state-of-the-art production technology and flexible service programs around the world, Loparex can offer you the right release liner for your specific application. |
Buy | €230M |
